Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/‐Ribavirin in Patients Receiving Concomitant Acid‐Reducing Agents in Phase 3 Trials: 2019. (October 2015) - Shiffman, Mitchell; Rustgi, Vinod; Bennett, Michael; Forns, Xavier; Asselah, Tarik; Vila, Ramon Planas; Pedrosa, Marcos; Neff, Guy; D'Amico, Ronald; Ball, Greg; Lopez‐Talavera, Juan Carlos; Reau, Nancy